Evidence map›Paper›PMID 40471555›Full record

ArticleFuture oncology (London, England)2025

Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.

Smith Giri, Dee Lin, Ruth Wangia Dixon, Nina Kim, Jessica Fowler, John Barron, Hiangkiat Tan, Chi Nguyen, Feven Asefaha, Shiva Vojjala and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Smith GiriDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Dee LinJohnson & Johnson, Horsham, PA, USA.
Ruth Wangia DixonCarelon Research, Wilmington, DE, USA.
Nina KimJohnson & Johnson, Horsham, PA, USA.
Jessica FowlerJohnson & Johnson, Horsham, PA, USA.
John BarronCarelon Research, Wilmington, DE, USA.
Hiangkiat TanCarelon Research, Wilmington, DE, USA.
Chi NguyenCarelon Research, Wilmington, DE, USA.
Feven AsefahaCarelon Research, Wilmington, DE, USA.
Shiva VojjalaCarelon Research, Wilmington, DE, USA.
Elissa E MinJohnson & Johnson, Horsham, PA, USA.
Bingcao WuJohnson & Johnson, Horsham, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundB-cell maturation antigen (BCMA)-targeted therapies were approved for triple-class exposed relapsed/refractory multiple myeloma (RRMM) after ≥4 lines of therapy.

methodsThis claims-based retrospective analysis examined clinical and economic burden among United States patients who met eligibility for BCMA-targeted therapies and started a new therapy between 1 January 2016 and 30 September 2022.

resultsOf 228 eligible patients (median age: 64, 52.6% male, 68.7% White), clinical burden was characterized by prevalent MM-related conditions and complications, and high treatment failure rate (44.7% in 6 months). Hospitalization rate increased from 48.3% to 71.1%, while healthcare costs per-member-per-month increased from $35,964 during 12-month baseline to $41,358 during follow-up (median: 11.8 months).

conclusionsPatients with heavily pre-treated RRMM endure high disease burden and could benefit from novel therapies.

Indexed as

B-Cell Maturation AntigenCost of IllnessMultiple MyelomaNeoplasm Recurrence, LocalAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHealth Care CostsHospitalizationHumansMaleMiddle AgedMolecular Targeted TherapyRetrospective StudiesB-Cell Maturation AntigenTNFRSF17 protein, humanBCMAbispecificCAR-Thealthcare costsRelapsed or refractory multiple myelomaretrospective studiesRRMMtriple-class exposed

Identifiers

PMID40471555
PMCPMC12239814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.